N/A N=51 Effects of Whole Sprouts on Airway Allergic Inflammation
Allergic Rhinitis · Asthma · Allergy
Primary: Exhaled Nitric Oxide Concentrations — 22; 19 ppb
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=24 Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion Body Myositis
Primary: Count of Adverse Events Reported — 109; 52 adverse events reported
N/A N=58 Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use
Snoring · Strep Throat
Primary: Healthcare Utilization — 5; 16; 5; 8 participants
Phase 4 N=40 Ulcer Prevention Study in Post Gastric Bypass Patients
Marginal Ulcers
Primary: Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia. — 17; 13 participants
Phase 3 N=50 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
Gastric Ulcer (GU) · Duodenal Ulcer (DU) · Anastomotic Ulcer (AU)
Primary: Disappearance of Heartburn at Week 8 by Patient Diaries — 2; 0; 0; 1 Participants
Phase 4 N=134 A Study Comparing CoQ10 Levels While Taking 3 Different Statins
Hypercholesterolemia
Primary: Changes in Plasma CoQ10 Levels — -96.70; -110.42; -103.91; -721.09 μg/g
N/A N=12 Impact of Breakfast Composition on Glycemic and Incretin Responses in Individuals With Type 2 Diabetes
Type 2 Diabetes
Primary: Plasma Glucose Level Post-meal (AUC [0-4]) — 28426; 33911 min*pg/ml
Phase 2 N=360 Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
Chronic Hepatitis B
Primary: Percentage of Participants With HBeAg Seroconversion at Endpoint . — 38.8; 28.6; 20.2 percentage of participants
Phase 3 N=802 Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen
Kidney Transplantation
Primary: GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard Regimen — 63.03; 68.59; 63.08 ml/min/1.73m² — p=< 0.0001
Phase 1 N=44 Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults
Malaria
Primary: Subjects With at Least One Adverse Event — 4; 4; 11; 15 Participants
Phase 3 N=1,034 Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Non Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) — 14.9; 17.3; 8.2; 10.4 Months — p=0.00024
Phase 2 N=64 Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Neuropathy of Sarcoidosis
Primary: Change in Corneal Nerve Fiber Area — -64.3; 533.8; 203.8; -170.0 µm^2
Phase 2 N=209 Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
Chronic Hepatitis B
Primary: The Proportion of Patients About HBeAg / Anti-HBe Seroconversion at the End of the Follow-up Period — 66.7; 100; 100; 38.7 percentage of participants
Phase 3 N=523 Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Postoperative Atrial Fibrillation
Primary: Total Number of Days in Hospital — 5.1; 5.0 days — p=0.76
N/A N=1,674 Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Carcinoma, Renal Cell
Primary: Number of Participants With Treatment-Related Adverse Events — 1599 Participants